Expression of p53 protein before and after PUVA treatment in psoriasis

Acta Dermato-Venereologica

Volumn 79, Issue 3, 1999, Pages 195-199

  Hannuksela Svahn, Anna ^a   Pääkkö, Paavo ^a   Autio, Pekka ^b   Reunala, Timo ^b   Karvonen, Jaakko ^a   Vähäkangas, Kirsi ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Ki67; Oral 8 methoxypsoralen PUVA; PCNA; Proliferation; Skin; Trioxsalen bath PUVA

Indexed keywords

CYCLINE; KI 67 ANTIGEN; METHOXSALEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA DAMAGE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PSORIASIS; PUVA; SKIN BIOPSY;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; PSORIASIS; PUVA THERAPY; SKIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032972108     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155599750010959     Document Type: Article

References (25)

1. 1. Pathak MA. Mechanisms of psoralen photosensitization reactions. Natl Cancer Inst Monogr 1984; 66: 41-46.
2. 2. Aubin F, Kripke ML, Ullrich SE. Activation of keratinocytes with psoralen plus UVA radiation induces the release of soluble factors that suppress delayed and contact hypersensitivity. J Invest Dermatol 1991; 97: 995-1000.
3. 3. Kirkland DJ, Creed KL, Mannisto P. Comparative bacterial mutagenicity studies with 8-methoxypsoralen and 4,5',8-trimethyl-psoralen in the presence of near-ultraviolet light and in the dark. Mut Res 1983; 116: 73-82.
4. 4. Hannuksela M, Stenbäck F, Lahti A. The carcinogenic properties of topical PUVA. A lifelong study in mice. Arch Dermatol Res 1986; 278: 347-351.
5. 5. Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Berne B, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91-93.
6. 6. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Cancer 1994; 73: 2759-2764.
7. 7. Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Berne B. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. Arch Dermatol 1992; 128: 1341-1344.
8. 8. Hannuksela A, Pukkala E, Hannuksela M, Karvonen J. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol 1996; 35: 685-689.
9. 9. Ko LJ, Prives C. p53: puzzle and paradigm. Genes and Development 1996; 10: 1054-1072.
10. 10. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
11. 11. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.
12. 12. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124-10128.
13. 13. Proby CM, Menagé H du P, et al. p53 immunoreactivity in cutaneous PUVA tumors is similar to that in other non-melanoma skin neoplasms. J Cut Pathol 1993; 20: 435-441.
14. 14. Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). J Invest Dermatol 1997; 109: 238-243.
15. 15. Soini Y, Kamel D, Pääkkö P, Lehto V.-P, Oikarinen A, Vähäkangas K. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994; 131: 514-520.
16. WAFI/CIPI in psoriasis and after the application of irritants and tape stripping. J Invest Dermatol 1993; 105: 274-279.
17. 17. Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-294.
18. 18. Swahney N, Hall PA. Ki67- structure, function, and new antibodies. J Pathol 1992; 168: 161-162.
19. 19. Shivji MKK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992; 69: 367-374.
20. 20. Hall PA, McKee PH, Menagé H du P, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207.
21. 21. Jonason AS, Kunala S, Price GJ, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 9: 14025-14029.
22. 22. Ren Z-P, Hedrum A, Pontén F, et al. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene 1996; 12: 765-773.
23. 23. Ren Z-P, Ahmadian A, Pontén F, et al. Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. Am J Pathol 1997; 150: 1791-1803.
24. 24. Freeman SE, Gange RW, Sutherland JC, Matzinger EA, Sutherland BM. Production of pyrimidine dimers in DNA of human skin exposed in situ to UVA radiation. J Invest Dermatol 1987; 88: 430-433.
25. 25. Campbell C, Quinn AG, Angus B, Farr PM, Rees JL. Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 1993; 53: 2697-2699.